Coartem® (artemether-lumefantrine) Baby becomes first malaria treatment approved for newborn babies and young infants Rapid approvals in eight African countries now expected under a special global ...

The GCAptAIN study did not meet its primary endpoint of sustained remission at Week 52 in adults with newly diagnosed or relapsing GCA1 Safety in GCA patients was consistent with known safety profile ...

Pluvicto® now publicly funded in provinces covering most Canadians, offering renewed hope to those facing progressive PSMA-positive metastatic castration-resistant prostate cancer Momentum builds ...

Utforsk mulighetene hos Novartis og Sandoz her. Se mer informasjon om stillinger hos Novartis Gene Therapies på GTx Career Search.

Novartis has been serving patients in Indonesia for more than 50 years, through our predecessor companies, Ciba and Sandoz.

By harnessing the power of radioactive atoms and applying it to advanced cancers through radioligand therapy, RLTs are able to deliver radiation to target cells anywhere in the body.

Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.

Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.

As Chief Audit Officer of Novartis, Teresa and her team provide risk-based assurance and advice on key strategic topics to the Board and management, acting as a key partner to the organization to help ...

Tafinlar + Mekinist, the worldwide targeted therapy leader in BRAF/MEK-inhibition, is the first and only therapy to be approved with a tumor-agnostic indication for adult and pediatric patients with ...

Entresto is the first and only therapy approved in the US to treat patients diagnosed with guideline-defined heart failure to include both those with heart failure with reduced ejection fraction ...

Cosentyx® (secukinumab) is the first new biologic treatment for hidradenitis suppurativa (HS) in nearly a decade, offering clinically meaningful results across the most debilitating symptoms1,2 ...